Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.
A money expert who studies companies just started watching Teva Pharmaceutical and thinks it looks like a good pick. They believe the stock could be worth $45, which helps investors think about whether the company seems fairly priced right now.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.